02.03.25 -- The Ins And Outs Of In-House Manufacturing: Building A Cell & Gene Production Facility

Explore our comprehensive methods for assessing DNA purity and integrity in AAV products to ensure the highest quality gene therapies for your patients.

When manufacturing adeno-associated virus, lenti- and adenoviral vectors, see how this HEK293 cell line is optimized for suspension culture and viral vector production, which can significantly reduce costs.

In this paper, we present the foundation of an mRNA-LNP platform for encoding and expressing therapeutic antibodies in vivo, eliminating the need for costly and time-consuming manufacturing.

We encourage the adoption and further optimization of this scalable AAV downstream process platform to enhance gene therapy applications, ensuring high product yield, quality, and compliance.

Examine how a partner with extensive capabilities and expertise adds value to drug development and helps to solve complex formulation, analytical, and manufacturing challenges our clients face.

Review how you can significantly increase AAV productivity and packaging efficiency for various AAV serotypes and client-specific Genes of Interest (GOIs) at the upstream production stage.

Learn how a robust understanding of the RNP’s critical process parameters and CQAs is crucial for ensuring product consistency, enhancing patient safety, and maintaining regulatory compliance.

Streamline CAR T-cell therapy development with integrated support for asset identification, IND submission, early-phase studies, and advanced real-time tracking solutions.

Ensure your business stays ahead in today’s complex regulatory environment by implementing robust regulatory affairs strategies that streamline compliance and product approvals.